Middle East Pharmaceutical Industries Co. announces its Interim Financial results for the Period Ending on 2026-06-30 (Six Months)

The increase was primarily driven by the continued expansion of the Company’s Private segment, which recorded revenue of SAR 99.8 million during the quarter, accounting for 73.1% of consolidated revenue and representing a 27.5% YoY increase from SAR 78.2 million. Growth was supported by continued customer base expansion, improved customer sales performance, disciplined pricing, and the ongoing optimization of the Company’s product portfolio. This was reflected in the gradual increase in the contribution of pharmaceutical products to the overall sales mix, supporting Avalon Pharma’s strategic focus on optimizing its product portfolio.

Revenue growth was further supported by the Export segment, which recorded revenue of SAR 18.0 million during Q2 2026, representing an increase of 11.9% YoY from SAR 16.1 million and accounting for 13.2% of consolidated revenue. The improvement reflects the successful enhancement of Export operations following the strategic rescheduling undertaken during the first quarter of 2026, alongside continued expansion across existing export markets and the preliminary activation of new markets.

The increase was primarily driven by higher revenues, which grew 16.0% YoY, coupled with a favorable product mix and effective cost optimization initiatives across the Company’s operations.

The increase in net profit during the quarter is primarily attributable to the 4.9% QoQ growth in revenue, together with lower General & Administrative expenses.

The improvement in profitability was partially offset by higher Selling & Distribution expenses as the Company continued to invest in business expansion during the quarter.

The increase was mainly driven by the Company’s Private segment, which recorded revenue of SAR 191.7 million during H1 2026, increasing 32.6% YoY, from SAR 144.5 million, and representing 71.9% of consolidated revenue.

The Public segment also delivered positive performance during the period, posting revenue of SAR 52.3 million, increasing by 5.7% YoY from SAR 49.5 million and accounting for 19.6% of consolidated revenue, as a result of increased government tender awards secured and delivered during the first half of the year.

Meanwhile, the Export segment recorded revenue of SAR 22.6 million during H1 2026, a growth of 7.5% YoY from SAR 21.0 million and representing 8.5% of consolidated revenue.

The increase was mainly driven by the 24.0% YoY growth in revenue, coupled with a favorable product mix and continued operational efficiencies across the Company, supporting improved profitability during the period.